HC Wainwright & Co. Maintains Buy on ITeos Therapeutics, Lowers Price Target to $44
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on ITeos Therapeutics (NASDAQ:ITOS) but lowers the price target from $54 to $44.
August 09, 2023 | 10:23 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
ITeos Therapeutics' price target has been lowered from $54 to $44 by HC Wainwright & Co., though the Buy rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained Buy rating indicates that the analyst still sees potential in the company, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100